A population of 741 million people makes Europe a huge market for drugmakers, yet most investors avoid European healthcare stocks in their portfolios. Is that a mistake? It could be, especially when it comes to Sanofi SA (NYSE:SNY), a French biopharma giant that's trading at a reasonable valuation and offers a market-trouncing dividend yield.
In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes and Motley Fool contributor Todd Campbell explain how drug approvals work in Europe and why Sanofi ought to be a stock that's on your radar.
A full transcript follows the video.
This video was recorded on May 16, 2018.
Kristine Harjes: Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day. I'm your Healthcare host, Kristine Harjes, and I have my usual sidekick, Todd Campbell, calling in. It's May 16th, and we're smack in the middle of an International Theme Week here on Industry Focus. Because we're a U.S.-based podcast talking about the U.S. stock market, we spend most of our time talking about domestic companies. But there's a whole world of stocks out there, and no portfolio is truly diversified without international exposure. So, this week, we decided to change things up by focusing on international stories.
Hot Small Cap Stocks To Buy Right Now: ATA Inc.(ATAI)
ATA Inc., through its subsidiaries, provides computer-based testing services in the People?s Republic of China. It offers services for the creation and delivery of computer-based tests utilizing its test delivery platform, proprietary testing technologies, and testing services; and provides logistical support services relating to test administration. The company?s computer-based testing services are used for professional licensure and certification tests in various industries, including information technology (IT) services, banking, securities, teaching, and insurance. Its e-testing platform integrates various aspects of the test delivery process for computer-based tests ranging from test form compilation to test scoring, and results analysis. ATA also provides career-oriented educational services, such as single course programs, degree major course programs, and pre-occupational training programs focusing on preparing students to pass IT and other vocational certification tests; test preparation and training programs and services to test candidates preparing to take professional certification tests in securities, futures, banking, insurance and teaching industries; online test preparation and training platform for the securities and banking industries; and test preparation software for the teaching industry. In addition, the company offers HR select employee assessment solution, an online system that utilizes its proprietary software and an inventory of test titles to help employers improve the efficiency and accuracy of their employee recruitment process. As of March 31, 2010, it had contractual relationships with 1,988 ATA authorized test centers. The company serves Chinese governmental agencies, professional associations, IT vendors, and Chinese educational institutions, as well as individual test preparation services. ATA Inc. was founded in 1999 and is based in Beijing, the People?s Republic of China.
Advisors' Opinion:- [By ]
ATAI Life Sciences NV (NASDAQ: ATAI) won't budge after its IPO. We were hot on this one out the gate, but it seems to have leveled off since the June 18 IPO date.
- [By Money Morning Staff Reports]
That's certainly the case with one of the top penny stocks this week, ATA Inc. (NASDAQ: ATAI). Last week, ATA locked in a 218% gain on high trading volume.
- [By Paul Ausick]
ATA Inc. (NASDAQ: ATAI) traded down about 14% Monday to set a new 52-week low of $0.82, based on revalued shares that closed at $0.72 on Friday but traded up about 250% on Monday at $2.53. Volume was more than 200 times the daily average of around 42,000. You’re on your own here to figure this one out.
Hot Small Cap Stocks To Buy Right Now: FuelCell Energy Inc.(FCEL)
FuelCell Energy, Inc., together with its subsidiaries, engages in the development, manufacturing, and sale of high temperature fuel cells for clean electric power generation primarily in South Korea, the United States, Germany, Canada, and Japan. The company offers proprietary carbonate Direct FuelCell Power Plants that electrochemically produce electricity from hydrocarbon fuels, such as natural gas and biogas. Its fuel cells operate on a range of hydrocarbon fuels, including natural gas, renewable biogas, propane, methanol, coal gas, and coal mine methane. The company also develops carbonate fuel cells, planar solid oxide fuel cell technology, and other fuel cell technologies. It provides its products to universities; manufacturers; mission critical institutions, such as correction facilities and government installations; hotels; and natural gas letdown stations, as well as to customers who use renewable biogas for fuel, including municipal water treatment facilities, br eweries, and food processors. The company was founded in 1969 and is headquartered in Danbury, Connecticut.
Advisors' Opinion:- [By Muslim Farooque]
FuelCell Energy (NASDAQ:FCEL) has been a public company for roughly three decades. However, it has yet to find its footing, marked by negative top-line, bottom-line, and cash flow growth. Since the beginning of the year, its performance has been abysmal, with poor operating results in the first half. The third quarter should be more of the same, which will put more pressure on FCEL stock.
- [By Joseph Griffin]
A number of analysts have commented on FCEL shares. Zacks Investment Research downgraded FuelCell Energy from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. B. Riley set a $3.00 target price on FuelCell Energy and gave the stock a “buy” rating in a research report on Friday, January 11th. Roth Capital downgraded FuelCell Energy from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a research report on Friday, November 23rd. Finally, Craig Hallum downgraded FuelCell Energy from a “buy” rating to a “hold” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. FuelCell Energy has an average rating of “Hold” and a consensus price target of $1.58.
ILLEGAL ACTIVITY WARNING: “FuelCell Energy (FCEL) Releases Earnings Results” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/4209243/fuelcell-energy-fcel-releases-earnings-results.html.About FuelCell Energy
- [By Paul Ausick]
FuelCell Energy Inc. (NASDAQ: FCEL) posted a drop of 8.5% in short interest during the period. Some 15.18 million shares were short as of February 15, about 14.8% of the total float. The stock closed at $0.47 on Wednesday, up about 3.3% for the day, in a 52-week range of $0.43 to $2.11. Shares traded up about 19% in the first two weeks of this month, and days to cover decreased from 12 to eight.
Hot Small Cap Stocks To Buy Right Now: China Metro-Rural Holdings Limited(CNR)
China Metro-Rural Holdings Limited, through its subsidiaries, primarily engages in the development and operation of agricultural logistics and trade centers in northeast China. It also involves in purchasing, processing, assembling, merchandising, and distributing pearls and jewelry products. The company markets its pearls and jewelry products to wholesale distributors and mass merchandisers in Europe, the United States, Hong Kong, and other parts of Asia. In addition, it develops, sells, and leases residential and commercial properties in Hong Kong and the People?s Republic of China. The company is based in Tsimshatsui, Hong Kong.
Advisors' Opinion:- [By Ethan Ryder]
Canadian National Railway (NYSE:CNI) (TSE:CNR) has been assigned a consensus recommendation of “Hold” from the twenty brokerages that are covering the firm, Marketbeat.com reports. Twelve equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $93.33.
- [By Stephan Byrd]
Several brokerages have updated their recommendations and price targets on shares of Canadian National Railway (TSE: CNR) in the last few weeks:
2/11/2019 – Canadian National Railway was given a new C$117.00 price target on by analysts at Morgan Stanley. 1/31/2019 – Canadian National Railway was given a new C$116.00 price target on by analysts at BMO Capital Markets. They now have a “market perform” rating on the stock. 1/30/2019 – Canadian National Railway had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a C$125.00 price target on the stock. 1/30/2019 – Canadian National Railway had its price target raised by analysts at TD Securities from C$125.00 to C$130.00. They now have a “buy” rating on the stock. 1/30/2019 – Canadian National Railway had its price target raised by analysts at CIBC from C$118.00 to C$119.00. 1/30/2019 – Canadian National Railway had its price target raised by analysts at JPMorgan Chase & Co. from C$116.00 to C$119.00. 1/14/2019 – Canadian National Railway had its price target raised by analysts at JPMorgan Chase & Co. from C$112.00 to C$116.00. 1/7/2019 – Canadian National Railway had its price target raised by analysts at Morgan Stanley from C$114.00 to C$115.00. 1/2/2019 – Canadian National Railway had its price target lowered by analysts at CIBC from C$120.00 to C$118.00. 12/19/2018 – Canadian National Railway had its price target lowered by analysts at National Bank Financial from C$119.00 to C$110.00. They now have a “sector perform” rating on the stock. 12/18/2018 – Canadian National Railway had its price target lowered by analysts at JPMorgan Chase & Co. from C$122.00 to C$112.00. 12/17/2018 – Canadian National Railway had its price target lowered by analysts at Royal Bank of Canada from C$130.00 to C$128.00.Shares of CNR stock traded up C$1.79 during tr
- [By Logan Wallace]
Canadian National Railway (NYSE:CNI) (TSE:CNR) – Analysts at Seaport Global Securities issued their Q1 2019 EPS estimates for shares of Canadian National Railway in a research note issued to investors on Wednesday, January 30th. Seaport Global Securities analyst M. Levin expects that the transportation company will earn $0.96 per share for the quarter. Seaport Global Securities also issued estimates for Canadian National Railway’s Q2 2019 earnings at $1.26 EPS, Q3 2019 earnings at $1.27 EPS and Q4 2019 earnings at $1.26 EPS.
- [By Ethan Ryder]
Canadian National Railway (NYSE:CNI) (TSE:CNR) – Equities research analysts at Desjardins boosted their Q3 2018 earnings per share estimates for shares of Canadian National Railway in a research note issued on Monday, October 8th. Desjardins analyst B. Poirier now anticipates that the transportation company will earn $1.09 per share for the quarter, up from their previous forecast of $1.09. Desjardins also issued estimates for Canadian National Railway’s FY2021 earnings at $5.66 EPS.
Hot Small Cap Stocks To Buy Right Now: Sky-mobi Limited(MOBI)
Sky-mobi Limited engages in the operation of a mobile application store in the People?s Republic of China. It works with handset companies to pre-install its Maopao mobile application store on handsets and with content developers to provide users with applications and content titles. The users of its Maopao store could browse, download, and purchase a range of applications and content, such as single-player games, mobile music, and books. The company?s Maopao store enables mobile applications and content to be downloaded and run on various mobile handsets with hardware and operating system configurations. It also operates a mobile social network community, the Maopao Community, where it offers localized mobile social games, as well as applications and content with social network functions to its registered members. The company owns proprietary mobile application technology in the cloud computing, the MRP format, and SDK development environment. As of March 31, 2011, it had entered into cooperation agreements with approximately 523 handset companies to pre-install Maopao. The company was formerly known as Profit Star Limited and changed its name to Sky-Mobi Limited in October 2010. Sky-mobi Limited was incorporated in 2007 and is headquartered in Hangzhou, China.
Advisors' Opinion:- [By Stephan Byrd]
Mobius (CURRENCY:MOBI) traded 5.5% higher against the dollar during the 24-hour period ending at 16:00 PM E.T. on February 21st. Mobius has a market cap of $6.06 million and $37,433.00 worth of Mobius was traded on exchanges in the last 24 hours. One Mobius token can now be purchased for $0.0118 or 0.00000298 BTC on popular cryptocurrency exchanges including GOPAX, Gate.io, BitMart and Stellarport. Over the last seven days, Mobius has traded up 22.4% against the dollar.
- [By Logan Wallace]
Mobius (CURRENCY:MOBI) traded up 0.1% against the dollar during the 24 hour period ending at 18:00 PM ET on February 11th. In the last week, Mobius has traded 3.1% lower against the dollar. One Mobius token can now be bought for approximately $0.0095 or 0.00000260 BTC on exchanges including OTCBTC, Gate.io, Stellar Decentralized Exchange and BitMart. Mobius has a total market capitalization of $4.89 million and approximately $19,445.00 worth of Mobius was traded on exchanges in the last day.
- [By Logan Wallace]
Mobius (CURRENCY:MOBI) traded 12.4% lower against the US dollar during the 24 hour period ending at 17:00 PM E.T. on September 25th. One Mobius token can now be bought for approximately $0.0265 or 0.00000414 BTC on major cryptocurrency exchanges including Gate.io, Kucoin, BitMart and GOPAX. Over the last week, Mobius has traded up 8.8% against the US dollar. Mobius has a market cap of $10.22 million and approximately $69,762.00 worth of Mobius was traded on exchanges in the last day.
Hot Small Cap Stocks To Buy Right Now: Achillion Pharmaceuticals Inc.(ACHN)
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Advisors' Opinion:- [By WWW.GURUFOCUS.COM]
For the details of MAK CAPITAL ONE LLC's stock buys and sells, go to https://www.gurufocus.com/guru/mak+capital+one+llc/current-portfolio/portfolio
These are the top 5 holdings of MAK CAPITAL ONE LLCSkyline Champion Corp (SKY) - 5,539,759 shares, 44.08% of the total portfolio. Shares reduced by 17.19%Agilysys Inc (AGYS) - 5,284,648 shares, 41.04% of the total portfolio. Achillion Pharmaceuticals Inc (ACHN) - 5,191,600 shares, 4.47% of the total portfolio. Shares added by 166.77%Yatra Online Inc (YTRA) - 1,938,559 shares, 4.22% of the total portfolio. Shares added by 1566.45%Maxwell Technologies Inc (MXWL) - 2,725,992 shares, 3.06% of th - [By Logan Wallace]
Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment